Given the different entry routes into the CNS and the overlapping roles of integrins, a combination of blocking antibodies to different integrins, chemokine receptor antagonists and molecules targeting VEGF/VEGFR-2 signaling will likely be the most effective approach to treat ALL in the CNS when used together with chemotherapy. The gene discussed is KDR; the disease is acute lymphoblastic leukemia.